
Available online at www.sciencedirect.com

Cellular Signalling 18 (2006) 401–408

Review

Signalling mechanisms regulating lipolysis

González-Yanes Carmen, Sánchez-Margalet Víctor*

Department of Medical Biochemistry and Molecular Biology, School of Medicine. Investigation Unit, Virgen Macarena University Hospital, Av. Sanchez Pizjuan 4, Seville 41009, Spain

Received 6 July 2005; accepted 19 August 2005  
Available online 22 September 2005

---

### Abstract

Adipose tissue plays an important role providing energy to other tissues and functioning as an energy reserve organ. The energy supply is produced by triglycerides stored in a large vacuole representing approximately 95% of adipocyte volume. In the fasting period, triglyceride hydrolysis produces glycerol and free fatty acids which are important oxidative fuels for other tissues such as liver, skeletal muscle, kidney and myocardium. Hormone-sensitive lipase (HSL) is the enzyme that hydrolyzes intracellular triacylglycerol and diacylglycerol, and is one of the key molecules controlling lipolysis. Hormones and physiological factors such as dieting, physical exercise and ageing regulate intensively the release of glycerol and free fatty acids from adipocytes. One of the best known mechanisms that activate lipolysis in the adipocyte is the cAMP dependent pathway. cAMP production is modulated by hormone receptors coupled to Gs/Gi family of GTP binding proteins, such as β-adrenergic receptors, whereas cAMP degradation is controlled by modulation of phosphodiesterase activity, increased by insulin receptor signalling. cAMP activates PKA which activates HSL by promoting its phosphorylation. Hormonal control of lipolysis can also be achieved by receptors coupled G proteins of the Gq family, through molecular mechanisms that involve PKC and MAPK, which are currently under investigation. cGMP and PKG have also been found to activate lipolysis in adipocytes. In this review we have compiled data from literature reporting both the classical and the alternative mechanisms of lipolysis.

© 2005 Elsevier Inc. All rights reserved.

Keywords: Lipolysis; Adipocytes; Adrenergic receptor; PKC; PKA

---

### Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
402 G.-Y. Carmen, S.-M. Victor / Cellular Signalling 18 (2006) 401–408

### 1. Introduction

The concentration of free fatty acid (FFA) in plasma is the result of a balance between lipolytic production, the uptake by the liver and the oxidation by muscle, heart, liver, and other tissues. Thus, a bad regulation of lipolysis can significantly affect the plasma FFA levels. A reduced lipolytic activity may lead to the accumulation of adipose tissue stores and this increase together with an impaired insulin-mediated inhibition of lipolysis may increase circulating FFA concentrations. Plasma FFA inhibits glucose utilization, mainly by acting on muscle tissue. Thus, an excessive fat oxidation in skeletal muscles inhibits pyruvate dehydrogenase that results in an insulin-stimulated diminished glucose uptake [54]. This unbalance on FFA and glucose plasma levels are closely related to obesity, insulin resistance, dyslipidaemia and type 2 diabetes mellitus. It has been proposed that chronically elevated FFA concentrations may reduce insulin secretion in type 2 diabetes [8]. In addition, there are differences in the type of adipose store and its contribution to insulin resistance. Visceral fat accumulation is strongly related with the increase of resistance against the anti-lipolytic action of insulin, being the FFA metabolism closely related with glucose utilization in patients with type 2 diabetes mellitus [45]. An accelerated rate of lipolysis in visceral adipose tissue produces an increase in FFA mobilisation to the portal vein, which connects visceral fat to the liver having undesirable effects on the liver, resulting in dyslipidaemia, hyperinsulinaemia, hyperglycaemia and hepatic insulin resistance [5].

The best known mechanism mediating lipolysis is the cAMP pathway. This mechanism implicates the coupling of hormone receptors in the plasma membrane to a Gs family of GTP-binding proteins. The αs subunit of G-protein stimulates an adenyl cyclase, which produces cAMP. The resulting increase in intracellular cAMP levels leads to the activation of a cAMP dependent protein kinase, PKA. Hormone sensitive lipase (HSL) and perilipin, are phosphorylated by PKA and this leads to catalysis of triglycerides and diglycerides breakdown, producing the subsequent release of FFA and glycerol [18,68].

On the other hand, other signalling pathways are involved in the lipolytic response of fat cells. One of these pathways involves PKC and can be stimulated by the phorbol ester PMA in both independent and dependent mitogen-activated protein kinases (MAPKs) way.

In addition to HSL, perilipins and adipocyte lipid binding protein (ALPB) play important roles on lipolysis regulation. Perilipins are located on the lipid droplet surface of fat cells and they are phosphorylated by PKA after its stimulation. This phosphorylation contributes positively to lipolysis since it prevents perilipins from blocking HSL translocation from the cytosol to lipid droplet. Some mechanisms that regulate lipolysis act on this protein either phosphorylating it or regulating its expression. For instance, TNF-α reduces perilipin expression in adipocytes, resulting in enhanced lipolysis, whereas PPARγ stimulates perilipin expression, resulting in an increase in triglycerides accumulation.

ALPB, is another protein that participates in lipolysis interacting with HSL, although the mechanisms for its regulation are less known.

In this review, we have summarized the reported signalling mechanisms regulating lipolysis, and the key proteins implicated on triglycerides hydrolysis.

### 2. Proteins participating in triacylglycerol hydrolysis

#### 2.1. Hormone sensitive lipase (HSL)

HSL is an enzyme with three isoforms ranging from 84 to 130 kDa. Acylglycerols are not the only substrate for HSL, it can hydrolyse also cholesteryl esters, retinyl esters, steroid esters and p-nitrophenyl esters [38]. HSL has three domains, a catalytic domain, a regulatory domain with several phosphorylation sites and an N-terminal variable domain involved in protein–protein and protein–lipid interactions [76].

Two serine residues in HSL were first identified that regulate its activity by PKA phosphorylation, Ser-563 (site 1) [27] and Ser-565 (site 2) [26]. Site 1 is phosphorylated in response to PKA after lipolytic stimulus. Site 2, which is phosphorylated in basal state, has been postulated as a regulator of site 1. The phosphorylation of site 2 prevents the phosphorylation of site 1, thus decreasing lipase activity [28]. In addition to PKA, other kinases can phosphorylate HSL at Ser-565, such as glycogen synthase kinase (GSK), AMP-dependent protein kinase (AMPK) and Ca2+/calmodulin-dependent protein kinase II (CaMK II), which does not seem to activate the enzyme [28].

Nevertheless, the HSL activity is not abolished by mutagenesis of Ser-563, which suggests the presence of other residues that could be phosphorylated by PKA. By site-directed mutagenesis and two-dimensional phosphopeptide mapping it has been shown that there are other Ser residues in HSL that can be phosphorylated in response to isoproterenol, such as Ser-659 and 660 and they have been found to be the activity-controlling sites of HSL [2].

Recently, another phosphorylation site in HSL has been identified. ERK activation causes HSL phosphorylation in the residue Ser-600, located in the middle of the regulatory module [36] and this phosphorylation by ERK produces a hydrolytic activity similar to that observed when HSL is phosphorylated by PKA [2].

The presence of HSL has been also demonstrated in rat muscle. HSL in muscle can be stimulated by adrenaline via β-adrenergic activation of PKA, but also by muscle contraction, although involving a different signalling mechanism. Thus, HSL activity may be stimulated by protein kinase C (PKC) via extracellular signal regulated kinase (ERK) [47].

#### 2.2. Perilipins

Upon a lipolytic stimulation, PKA phosphorylates HSL, which translocate from the cytosol, where the enzyme is widely distributed, to the lipidic vacuole, which is formed by neutral lipids, surrounded by a phospholipid monolayer.

Inside the monolayer there are absorbed proteins named perilipins [11]. The perilipins belong to a family of hydrophobic lipid droplet-associated phosphoproteins that are phosphorylated by PKA in multiple residues. These proteins are specific for adipocytes and are closely associated with the periphery of lipid storage droplets [35]. The function of perilipins is to prevent lipolysis in basal conditions, favouring the lipid deposition. When HSL translocates to lipidic drop surface, perilipins, which act as a barrier to enzyme action, are phosphorylated by PKA and lose their blocking capability [49]. Perilipins are required to maximize the storage of triacylglycerols in adipose tissue.

Perilipin knockout mice have a reduced adipose tissue mass and high levels of basal lipolysis in a constitutive way [51,71]. These mice are resistant to diet-induced obesity when they are compared to control mice. Moreover ectopic expression of perilipin in 3T3-L1 pre-adipocytes that normally have not perilipins produces numerous lipid droplets tightly clustered in one or two regions of the cytoplasm with perilipins localized on the surface of these lipid droplets, increasing the half-life of stored triacylglycerol deposits [9].

Perilipin has been found to be a target gene for peroxisome proliferator-activated receptor-gamma (PPARγ) [13]. Treatment of differentiating 3T3-L1 adipocytes with an agonist of PPARγ, increases perilipin gene expression. Perilipin has a PPARγ-responsive element in the promoter region, being PPARγ2 the most potent regulator of all members of the PPAR family [3].

The expression of perilipin, studied by Western-blot in 3T3-L1 adipocytes is diminished in response to TNF-alpha treatment. Pretreatment of adipocytes with specific inhibitors of MAPK activity such as extracellular signal-regulated kinase (ERK or p44/42) significantly blocked the TNF-α-induced reduction of perilipin A protein level suggesting that activation of the ERK pathway is an early event in the mechanism of TNF-α-induced lipolysis [67]. Moreover, in rodent cells TNF-α enhances lipolysis through down-regulation of the expression of perilipin. It has been shown that TNF-α-mediated lipolysis is dependent on down-regulation of perilipin expression via p44/42 and Jun kinases (JNK) [56].

### 2.3. Adipocyte lipid binding proteins (ALBP)

In addition to perilipins, there are cytosolic proteins that specifically bind lipids named Adipocyte Lipid Binding Proteins (ALBP). These proteins interact with HSL favouring the translocation from cytosol to lipidic droplet [63]. ALBP are low molecular weight proteins (15 kDa), that form 1:1 complex with fatty acids, retinoids and other hydrophobic ligands. ALBP are expressed in a large variety of tissues such as adipose tissue, liver, intestine, heart and brain. These proteins have a structure consisting of a β barrel structure with an hydrophobic internal cavity where the fatty acids penetrate occupying only one third of accessible volume.

The function of these proteins is to sequester fatty acids inside the cytosol to protect the cell from its harmful effect, making intracellular lipid traffic easier [7].

ALBP increases the hydrolytic activity of HSL through its ability to bind and sequester fatty acids and via specific protein-protein interaction. Thus, HSL and ALBP constitute a functionally important lipolytic complex [62]. In the absence of fatty acids, no ALBP-HSL association can take place for any ALBP form. A-ALBP and E-ALBP adipocyte and epithelial isoforms of ALBP that are expressed in adipose tissue, physically associate with HSL in a fatty acid-dependent manner with high affinity and specificity. It seems that HSL activation by ALBP is due to the removal of product inhibition [41].

It has been shown that mice that do not express ALBP present great deficiencies in TNFα expression and even though they develop diet induced obesity, they do not develop insulin resistance or diabetes as do the obese mice that express the protein correctly. These results imply a relation between obesity and insulin resistance that may be mediated by ALBP [39].

## 3. Signalling pathways implicated in lipolysis regulation

### 3.1. Mechanisms producing CAMP elevation levels

#### 3.1.1. Gs dependent mechanisms

A large number of hormones, peptides and neurotransmitters interact with membrane receptors coupled to several GTP-binding proteins to transduce the signal. The activation of Gs protein is the best-known mechanism that mediates lipolytic activation. Catecholamines, adrenaline and noradrenaline are the paradigm of this group of hormones. They have three subtypes of β receptors and two subtypes of α receptors. The β-AR or β-adrenoceptors (β-AR) are expressed mainly in white and brown adipose tissue [20,24,74]. The positive regulation of lipolysis by catecholamines using the Gs/AC/PKA/HSL pathway involves β1, β2 and β3-AR (Fig. 1). The three β receptors are coupled to a Gs-protein, they transmit an activation signal to adenylyl cyclase (AC) increasing cAMP production. Then a cAMP-dependent protein kinase (PKA) is activated and this finally leads to phosphorylation and activation of HSL and perilipin A [6,43,58,69]. HSL breaks the triglycerides stored in adipocytes thus producing glycerol and FFA.

Other possible mechanisms of lipolysis activation in a long term basis imply the overexpression of β-AR. Thus, testosterone stimulates lipolysis by increasing of β-ARs [14] and TNFα stimulates lipolysis for more than 6 h through a different activation of three subtypes of catecholamine receptors. In 3T3-F442A (a murine line of adipocytes), TNFα decreases two times the number of β3 receptors, and increases by 4.5 times the density of β2 receptors. These effects lead to an acute stimulation of lipolysis and a negative control of several key hormones in the lipogenic route [37].

On the other hand, Gs expression level is also an important parameter that affects the lipolytic activity. There are some pathologic situations, such as PTH, TSH, gonadotropins and glucagon resistance and skeletal defects among other clinical manifestation, where one of the principal features is a decrease on Gs expression by a mutation in the gene encoding Gαs. The lipolytic activity both basal and adrenaline-stimulated are markedly decreased in these cases and they are very similar

G.-Y. Carmen, S.-M. Victor / Cellular Signalling 18 (2006) 401–408

Fig. 1. Gαs/cAMP/PKA/HSL pathway to lipolysis.

to that observed in obese patients with Gs deficiency. Moreover, Gs protein itself seems to be involved in the decreased lipolysis observed in some cases of obesity [10].

3.2. Mechanisms producing CAMP diminished levels

3.2.1. Gi dependent mechanisms

The β3-adrenoceptor has an additional signaling pathway that can also regulate lipolysis. Experiments made in intact adipocytes show that cAMP accumulation stimulated by a beta 3-selective agonist, is potentiated by pertussis toxin (PTX), indicating that Gi proteins can limit β3-stimulated adenyl cyclase activity [12]. This double coupling allows a simultaneous transduction of independent signals. In Chinese hamster ovary/K1 cells the stimulation of human β3-AR specifically activates ERK1/2. This activation is sensitive to pertussis toxin, wortmannin, LY294002 and PD98059, indicating that β3-adrenoceptor coupled to Gi acts through mitogen-activated protein kinase kinase and phosphatidylinositol-3 kinase (PI3K) [31]. Similarly, PTX-sensitive stimulation of MAP kinase has been observed in 3T3-F442A adipocytes and HEK-293 cells that express human β3-AR [66]. In these studies, it has been suggested that the mechanism whereby β3/Gi activation leads to ERK activation involves βγ subunits that can interact with PI3K. This coupling of β3-AR to Gi restrains Gs-mediated activation of adenyl cyclase and initiates an additional signal transduction pathway, linking β3 receptor with cellular proliferation, apoptosis and differentiation. Nonetheless, this Gi pathway for β3 receptors is not functional in all cellular systems. Thus, in brown adipocytes it has been shown that β3 receptor-ERK1/2 activation is produced via cAMP/protein kinase A and not through β3/Gi association, being this ERK activation mechanism dependent of Src [48].

The α2 AR also inhibits lipolysis coupled to a Gi protein that inhibits adenyl cyclase and all the sequential steps that lead to HSL activation. These receptors present higher affinity for physiological amines and are stimulated by the minor concentration of catecholamines. A possible explanation for the existence of two opposite mechanisms that affect lipolysis in the same cell may be that, in this way, the α2 receptors exert a permanent basal inhibition of lipolysis [46]. Adenosine is another lipolysis inhibitor that has a Gi protein coupled receptor in the adipocyte. In this way, basal lipolysis is normally inhibited by endogenous adenosine spontaneously produced by the adipocyte [59].

An activation of lipolysis may take place through TNFα mediated decrease of Gi concentration coupled to adenosine receptor which blocks the continuous lipolysis inhibition signal [29].

3.2.2. PDE dependent mechanisms

Phosphodiesterase (PDE) is phosphorylated and activated in response to agents that increase the cAMP, such as catecholamines, and represent one of the desensitization mechanisms by these hormones in a short time basis [64]. The role of the PDE is to hydrolyze the intracellular cAMP produced when the adipose cells receive a lipolytic stimulus (Fig. 2). This enzyme is comprised of a group of 14 isoforms, belonging to 7 families of genes [50]. The difference among them is due to variations in its primary structures, different affinities for cAMP and cGMP, different response to its effectors and sensitivity to its inhibitors. The PDE3 isoform has a high affinity for cAMP and cGMP, meanwhile PDE4 only has affinity for cAMP [15]. There are two variants of PDE3 isoforms, which are produced by the expression of different genes PDE3A and PDE3B. The later variant is expressed in adipocytes, in addition to other cells sensitive to insulin such as the hepatocyte and pancreatic cells and is the object of an important hormonal regulation. PDE3B is regulated in short-term by phosphorylation after insulin stimulation, and agents that increase cAMP in adipocytes, hepatocytes, and platelets. In rat adipocytes PDE3B is phosphorylated by a protein kinase (PDE3BK) in the Ser 302 residue. In this signalling pathway IRS-1 and PIP3 are implicated [15]. Later, it was found that PDE3BK is actually the protein kinase B (PKB/Akt) [16]. Little is known about the long time regulation of PDE3B. Studies in diabetic

G.-Y. Carmen, S.-M. Victor / Cellular Signalling 18 (2006) 401–408

Fig. 2. PDE pathway to lipolysis.

patients have shown a decrease in PDE activity that is normalized after the treatment with insulin or oral antidiabetic drugs [19]. A decrease in PDE activity and its mRNA seems to be associated to insulin resistance [70]. Thyroid hormones also affect PDE activity. In rat adipocytes from hyperthyroid animals, the PDE3B activity decreases, while lipolysis, stimulated by catecholamines, is greater [34]. Accordingly, in hypothyroid animals, the effect on PDE3B activity and lipolysis is the opposite [73].

Another signal affecting PDE3B is TNFα. A mechanism suggested for TNFα activated lipolysis is the negative regulation of PDE3B [53]. In 3T3-L1 a physiological concentration of TNFα produces a maximal decrease in activity and expression of PDE3B that correlates with PKA activation and lipolysis stimulation in a long term [53].

PDE3B is also affected by intracellular Ca²⁺ concentration. In human adipocytes intracellular Ca²⁺ has an anti-lipolytic effect that is mediated by PDE3B activation [75].

### 3.2.3. cAMP independent mechanisms

#### 3.2.3.1. Gq dependent mechanisms.
Lipolytic activity independent of adrenergic activity has been seen in β1/β2/β3-adrenoceptors knockout mice [42]. These mice are obese and cold-sensitive but keep intact a good lipolytic response to fasting that might be due to an over-compensation by other lipolytic hormones or other catecholamine receptors.

The α1-adrenoceptors acts on lipolysis through a mechanism that is not very clear at the moment [21]. α1-ARs stimulation are known to produce an increase in intracellular Ca²⁺ and PKC translocation to membranes through phosphoinositides hydrolysis [4]. In other hand, Norfenefrine, an α1-AR specific agonist, causes an increase in glycerol level in adipose tissue that is similar to that observed with the physiologic α(1,2)-beta(1)-AR agonist noradrenaline. Therefore, there are data supporting the idea that α1-AR is involved in the regulation of lipolysis. In this line, transgenic BDF-1 mice that do not express Gαq in liver and white adipose tissue suffer increased body mass and hyperadiposity within 5 weeks of birth, which persisted throughout adult life. In these mice adipocytes display reduced lipolytic responses. This could represent a new lipolytic regulation mechanism via phosphoinositide hydrolysis and activation of protein kinase C [25]. Moreover, classical PKC activity has also been implicated in another typical PKA mediated signalling pathway, i.e., the activation by phosphorylation of CREB (cAMP-response-element-binding protein), a transcription factor that mediates the β-adrenergic induction of gene expression. More precisely, α1-AR receptor via cPKC activation, phosphorylates CREB in Ser 133, therefore activating this pathway in response to α1 stimulation [72].

Consistent with these results we have found, in rat white adipose tissue, that pancreastatin (PST), a Chromogranin A derived peptide, produces a lipolytic effect without AMPc elevation levels [57]. PST binds a plasma membrane receptor in adipocyte, which is coupled, to a Gαq/11 heterotrimeric protein. Next, Gαq/11 activates a PLC-β3 isoform that produces IP₃ and Ca²⁺ elevation intracellular level and classical isoforms of PKC activation (Fig. 3). Finally, PST produces ERK1/2 activation by a PKC dependent mechanism. Nonetheless we do not know whether the PST stimulated lipolysis is mediated through ERK1/2 activation [33].

On the other hand, it has been shown that adenylate cyclase activity in purified rat adipocyte membranes is stimulated by the calcium- and phospholipid-dependent enzyme protein kinase C [52]. Besides, a possible role of ERK1/2 cannot be ruled out. Indeed, in 3T3-L1 adipocytes, in addition to cAMP/PKA pathway, the PMA/PKC/MAPK pathway also seems to play a role on lipolysis stimulation. When both pathways are activated, they act synergistically on lipolysis stimulation, although they are normally independent. Phosphorylation of HSL by the second mechanism is similar to produced by PKA but not the ability to phosphorylate perilipins [23].

G.-Y. Carmen, S.-M. Victor / Cellular Signalling 18 (2006) 401–408

PST receptor  
$\alpha_{1}$-AR  

Fig. 3. Gαq/PLC/PKC pathway to lipolysis.

Normally, ERK1/2 is activated through a Ras-calcium and tyrosine kinase-dependent pathway for G<sub>q/11</sub>-coupled receptors. Nonetheless, in isolated rat hepatocytes, the α1-adrenergic activation by noradrenaline of MAPK can be blocked by a specific PKC inhibitor confirming that α1-adrenergic stimulation of MAPK can proceed through a PKC-dependent pathway [55]. In brown adipocytes α1-AR also activates ERK1/2 via Src in a Gi-independent way [48].

In HEK-293 cells, α1B-AR produces ERK1/2 activation, which is dependent of phospholipase C, intracellular Ca<sup>2+</sup> and protein tyrosine kinases such as Pyk2 that stimulates c-Src. In this system an elevation in Ca<sup>2+</sup> levels seems to initiate the ERK1/2 activation followed by an interaction between Ca<sup>2+</sup>-calmodulin and the protein tyrosine kinase Pyk2 [17].

Supporting this positive lipolytic role of calcium in 3T3-L1 preadipocytes, magnolol, a phenolic compound isolated from Magnolia obovata that inhibits tumour cell invasion in vitro, has a lipolytic effect, which is not mediated by PKA since it does not increase cAMP levels. This compound produces an increase in the intracellular Ca2+ concentration in a PLC dependent manner. CaMK, ERK1 and ERK2 seem to be involved in the mechanisms underlying the lipolytic action of this compound [40].

The connection between Ca2+ and ERK is also described in other studies. It has been shown that Ca2+ induce ERK activation through CaMKII [1] and subsequent phosphorylation of p56 (Lck) [22] and that CaMKIV isoforms can activate ERK through B-Raf activation [65].

### 4. Other mechanisms for the regulation of lipolysis

An additional mechanism of lipolysis has been recently described in human adipocytes. Thus, the atrial natriuretic peptide (ANP) has been found to have a potent lipolytic effect in vivo and in vitro [60]. On differentiated human preadipocytes, ANP-stimulated lipolysis was associated with an increased phosphorylation of HSL and perilipin A, and was strongly decreased by inhibition of cGMP-dependent protein kinase I (PKG-I) [61].

The nitric oxide, NO·, (that can exist in three different forms, NO+, NO· and NO−) has two contrasting effects on lipolysis. The NO+ donors such as nitrosothiols are known to increase basal lipolysis through a mechanism different from cGMP. It could be explained by S-nitrosilation of SH groups of proteins implicated in lipolysis that is observed when adipose tissue is exposed to N-etilmaleimide, an alquilant agent of thiol groups that produces basal lipolysis stimulation. A possible candidate to undergo S-nitrosilation seems to be cGMP-inhibited PDE, which contains thiol groups critical for their function. The NO· donors such as l-propamina,3-(2-hidroxi-2-nitroso-1-propilhidrazina) (PAPA-NONOate) do not affect basal lipolysis [32].

On the other hand, when the effect of NO+ and NO− on isoproterenol-stimulated lipolysis is studied, an inhibitory effect is observed that can be explained by the S-nitrosilation property of thiol groups. In this case, the β-ARs which contains key thiol groups for their activity seems to be the target. Nevertheless, G-proteins cannot be ruled out as possible candidates of nitrosilation. Besides, NO· inhibits, in a dose-dependent way, stimulated lipolysis by several effectors such as forskoline or isoproterenol [30], but it seems to use other mechanism different from NO+ and NO− species, leading to a process that decreases cAMP levels. Pretreatment of isoproterenol with nitric oxide blocks the lipolytic activity of catecholamine, through a sequence of oxidation reactions that finally lead to its inactivation as it has been observed by spectroscopy techniques and HPLC analysis [44].

### 5. Conclusions

An accurate control of lipolysis is essential to keep a normal level of FFA. A disorder in this regulation can produce an elevation on plasma FFA that may promote insulin resistance and cardiovascular complications. Here we have

reviewed the classical mechanisms controlling lipolytic activity and the more recent signalling pathways that are still under study. The classical activation of HSL by PKA is complicated with the participation of other protein kinases as ERK1/2 that can also to activate HSL by phosphorylation in Ser residues. Intriguingly, some ERK1/2 dependent mechanisms activated by β3-AR coupled to Gi are capable to inhibit lipolysis. Besides these catecholamines pathways are implicated on proliferation, differentiation and apoptosis. On the other hand, insulin inhibits lipolysis by activation of PDE3B and also activates ERK pathway. Other mechanisms of lipolysis regulation are dependent of PKC and PKG. The first can also lead to ERK activation and the latter is the mechanism whereby ANP stimulates lipolysis. In conclusion, even though we know better the regulation of lipolysis, further studies are needed in order to fully understand the signalling mechanisms that lead the adipocyte to a lipolytic response.

**References**

[1] S.T. Abraham, H.A. Benscoter, C.M. Schworer, H.A. Singer, Circ. Res. 81 (1997) 575.
[2] M.W. Anthonsen, L. Ronnstrand, C. Wernstedt, E. Degerman, C. Holm, J. Biol. Chem. 273 (1998) 215.
[3] N. Arimura, T. Horiba, M. Imagawa, M. Shimizu, R. Sato, J. Biol. Chem. 279 (2004) 10070.
[4] P. Arner, Am. J. Clin. Nutr. 55 (1992) 228S.
[5] P. Arner, Diabetes Metab Res. Rev. 18 (Suppl 2) (2002) S5.
[6] P. Belfrage, G. Fredrikson, N.O. Nilsson, P. Stralfors, FEBS Lett. 111 (1980) 120.
[7] D.A. Bernlohr, M.A. Simpson, A.V. Hertzel, L.J. Banaszak, Annu. Rev. Nutr. 17 (1997) 277.
[8] E.E. Blaak, Proc. Nutr. Soc. 62 (2003) 753.
[9] D.L. Brasaemle, B. Rubin, I.A. Harten, J. Gruia-Gray, A.R. Kimmel, C. Londos, J. Biol. Chem. 275 (2000) 38486.
[10] J.C. Carel, C. Le Stunff, L. Condamine, E. Mallet, J.L. Chaussain, P. Adnot, M. Garabedian, P. Bougnères, J. Clin. Endocrinol. Metab. 84 (1999) 4127.
[11] G.B. Carey, Adv. Exp. Med. Biol. 441 (1998) 157.
[12] A. Chaudhry, R.G. MacKenzie, L.M. Georgic, J.G. Granneman, Cell Signal 6 (1994) 457.
[13] K.T. Dalen, K. Schoonjans, S.M. Ulven, M.S. Weedon-Fekjaer, T.G. Bentzen, H. Koutnikova, J. Auwerx, H.I. Nebb, Diabetes 53 (2004) 1243.
[14] G. De Pergola, Int. J. Obes. Relat. Metab. Disord. 24 (Suppl 2) (2000) S59.
[15] E. Degerman, P. Belfrage, V.C. Manganiello, J. Biol. Chem. 272 (1997) 6823.
[16] E. Degerman, T.R. Landstr inverted question markm, J. Wijkander, L.S. Holst, F. Ahmad, P. Belfrage, V. Manganiello, Methods 14 (1998) 43.
[17] G.J. Della Rocca, T. van Biesen, Y. Daaka, D.K. Luttrell, L.M. Luttrell, R.J. Lefkowitz, J. Biol. Chem. 272 (1997) 19125.
[18] J.J. Egan, A.S. Greenberg, M.K. Chang, S.A. Wek, M.C. Moos Jr., C. Londos, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 8537.
[19] P. Engfeldt, P. Arner, J. Bolinder, J. Ostman, J. Clin. Endocrinol. Metab. 55 (1982) 983.
[20] B. Feve, L.J. Emorine, F. Lasnier, N. Blin, B. Baude, C. Nahmias, A.D. Strosberg, J. Pairault, J. Biol. Chem. 266 (1991) 20329.
[21] M. Flechtner-Mors, C.P. Jenkinson, A. Alt, G. Adler, H.H. Ditschuneit, J. Pharmacol. Exp. Ther. 301 (2002) 229.
[22] R.A. Franklin, P.A. Atherfold, J.A. McCubrey, Mol. Immunol. 37 (2000) 675.
[23] K. Fricke, A. Heitland, E. Maronde, Endocrinology (2004).
[24] J. Galitzky, C. Carpene, A. Bousquet-Melou, M. Berlan, M. Lafontan, Fundam. Clin. Pharmacol. 9 (1995) 324.
[25] P.A. Galvin-Parton, X. Chen, C.M. Moxham, C.C. Malbon, J. Biol. Chem. 272 (1997) 4335.
[26] A.J. Garton, D.G. Campbell, D. Carling, D.G. Hardie, R.J. Colbran, S.J. Yeaman, Eur. J. Biochem. 179 (1989) 249.
[27] A.J. Garton, D.G. Campbell, P. Cohen, S.J. Yeaman, FEBS Lett. 229 (1988) 68.
[28] A.J. Garton, S.J. Yeaman, Eur. J. Biochem. 191 (1990) 245.
[29] S. Gasic, B. Tian, A. Green, J. Biol. Chem. 274 (1999) 6770.
[30] N. Gaudiot, A.M. Jaubert, E. Charbonnier, D. Sabourault, D. Lacasa, Y. Giudicelli, C. Ribiere, J. Biol. Chem. 273 (1998) 13475.
[31] C.C. Gerhardt, J. Gros, A.D. Strosberg, T. Issad, Mol. Pharmacol. 55 (1999) 255.
[32] Y. Giudicelli, D. Provins, R. Nordmann, Biochem. Pharmacol. 24 (1975) 1029.
[33] C. Gonzalez-Yanes, V. Sanchez-Margalet, Diabetes 49 (2000) 1288.
[34] A. Goswami, I.N. Rosenberg, Endocrinology 103 (1978) 2223.
[35] A.S. Greenberg, J.J. Egan, S.A. Wek, N.B. Garty, E.J. Blanchette-Mackie, C. Londos, J. Biol. Chem. 266 (1991) 11341.
[36] A.S. Greenberg, W.J. Shen, K. Muliro, S. Patel, S.C. Souza, R.A. Roth, F.B. Kraemer, J. Biol. Chem. 276 (2001) 45456.
[37] K.E. Hadri, A. Courtalon, X. Gauthereau, A.M. Chambaut-Guerin, J. Pairault, B. Feve, J. Biol. Chem. 272 (1997) 24514.
[38] C. Holm, T. Osterlund, H. Laurell, J.A. Contreras, Annu. Rev. Nutr. 20 (2000) 365.
[39] G.S. Hotamisligil, R.S. Johnson, R.J. Distel, R. Ellis, V.E. Papaioannou, B.M. Spiegelman, Science (1996) 1377.
[40] S.H. Huang, W.J. Shen, H.L. Yeo, S.M. Wang, J. Cell Biochem. 91 (2004) 1021.
[41] A.E. Jenkins-Kruchten, A. Bennars-Eiden, J.R. Ross, W.J. Shen, F.B. Kraemer, D.A. Bernlohr, J. Biol. Chem. 278 (2003) 47636.
[42] M. Jimenez, B. Leger, K. Canola, L. Lehr, P. Arboit, J. Seydoux, A.P. Russell, J.P. Giacobino, P. Muzzin, F. Preitner, FEBS Lett. 530 (2002) 37.
[43] M. Kawamura, D.F. Jensen, E.V. Wancewicz, L.L. Joy, J.C. Khoo, D. Steinberg, Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 732.
[44] P. Klatt, J. Cacho, M.D. Crespo, E. Herrera, P. Ramos, Biochem. J. 351 (Pt 2) (2000) 485.
[45] S. Kurioka, Y. Murakami, M. Nishiki, M. Sohmiya, K. Koshimura, Y. Kato, Endocr. J. 49 (2002) 459.
[46] M. Lafontan, P. Barbe, J. Galitzky, G. Tavernier, D. Langin, C. Carpene, A. Bousquet-Melou, M. Berlan, Hum. Reprod. 12 (Suppl 1) (1997) 6.
[47] J. Langfort, M. Donsmark, T. Ploug, C. Holm, H. Galbo, Acta Physiol. Scand. 178 (2003) 397.
[48] J.M. Lindquist, J.M. Fredriksson, S. Rehnmark, B. Cannon, J. Nedergaard, J. Biol. Chem. 275 (2000) 22670.
[49] C. Londos, D.L. Brasaemle, C.J. Schultz, J.P. Segrest, A.R. Kimmel, Semin. Cell Dev. Biol. 10 (1999) 51.
[50] V.C. Manganiello, T. Murata, M. Taira, P. Belfrage, E. Degerman, Arch. Biochem. Biophys. 322 (1995) 1.
[51] J. Martinez-Botas, J.B. Anderson, D. Tessier, A. Lapillonne, B.H. Chang, M.J. Quast, D. Gorenstein, K.H. Chen, L. Chan, Nat. Genet. 26 (2000) 474.
[52] S. Naghshineh, M. Noguchi, K.P. Huang, C. Londos, J. Biol. Chem. 261 (1986) 14534.
[53] L.T. Rahn, J. Mei, M. Karlsson, V. Manganiello, E. Degerman, Biochem. J. 346 (Pt 2) (2000) 337.
[54] P.J. Randle, Diabetes Metab. Rev. 14 (1998) 263.
[55] A. Romanelli, W.G. van de, Metabolism 46 (1997) 548.
[56] M. Ryden, E. Arvidsson, L. Blomqvist, L. Perbeck, A. Dicker, P. Arner, Biochem. Biophys. Res. Commun. 318 (2004) 168.
[57] V. Sanchez-Margalet, C. Gonzalez-Yanes, Am. J. Physiol. 275 (1998) E1055.
[58] R.J. Schimmel, C.A. Buhlinger, R. Serio, J. Lipid Res. 21 (1980) 250.
[59] U. Schwabe, R. Ebert, H.C. Erbler, Adv. Cycl. Nucleotide Res. 5 (1975) 569.
[60] C. Sengenes, M. Berlan, G. De, I. Lafontan, M. Galitzky, FASEB J. 14 (2000) 1345.

[61] C. Sengenes, A. Bouloumie, H. Hauner, M. Berlan, R. Busse, M. Lafontan, J. Galitzky, J. Biol. Chem. 278 (2003) 48617.

[62] W.J. Shen, Y. Liang, R. Hong, S. Patel, V. Natu, K. Sridhar, A. Jenkins, D.A. Bernlohr, F.B. Kraemer, J. Biol. Chem. 276 (2001) 49443.

[63] W.J. Shen, K. Sridhar, D.A. Bernlohr, F.B. Kraemer, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 5528.

[64] C.J. Smith, V. Vasta, E. Degerman, P. Belfrage, V.C. Manganiello, J. Biol. Chem. 266 (1991) 13385.

[65] T.R. Soderling, Trends Biochem. Sci. 24 (1999) 232.

[66] K.J. Soeder, S.K. Snedden, W. Cao, G.J. Della Rocca, K.W. Daniel, L.M. Luttrell, S. Collins, J. Biol. Chem. 274 (1999) 12017.

[67] S.C. Souza, H.J. Palmer, Y.H. Kang, M.T. Yamamoto, K.V. Muliro, K.E. Paulson, A.S. Greenberg, J. Cell Biochem. 89 (2003) 1077.

[68] D. Steinberg, Adv. Exp. Med. Biol. 26 (1972) 77.

[69] P. Stralfors, P. Belfrage, J. Biol. Chem. 258 (1983) 15146.

[70] Y. Tang, H. Osawa, H. Onuma, T. Nishimiya, M. Ochi, H. Makino, Diabetes 48 (1999) 1830.

[71] J.T. Tansey, C. Sztalryd, J. Gruia-Gray, D.L. Roush, J.V. Zee, O. Gavrilova, M.L. Reitman, C.X. Deng, C. Li, A.R. Kimmel, C. Londos, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6494.

[72] H. Thonberg, J.M. Fredriksson, J. Nedergaard, B. Cannon, Biochem. J. 364 (2002) 73.

[73] R.G. Van Inwegen, G.A. Robison, W.J. Thompson, J. Biol. Chem. 250 (1975) 2452.

[74] L. Van I, A. Van Witzenburg, G. Vauquelin, J. Pharmacol. Exp. Ther. 262 (1992) 552.

[75] B. Xue, A.G. Greenberg, F.B. Kraemer, M.B. Zemel, FASEB J. 15 (2001) 2527.

[76] S.J. Yeaman, Biochem. J. 379 (2004) 11.
